The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk of progression to myelofibrosis and acute myeloid leukemia in patients with essential thrombocythemia and polycythemia vera with prior malignancy.
M. A. Cherry
No relevant relationships to disclose
H. Pham
No relevant relationships to disclose
H. Kantarjian
No relevant relationships to disclose
J. E. Cortes
No relevant relationships to disclose
S. Pierce
No relevant relationships to disclose
L. Zhou
No relevant relationships to disclose
S. Verstovsek
No relevant relationships to disclose